Immunome Quarterly Income Statement
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunome revenue and earnings
In the quarter ended Jun 30, 2026, Immunome generated $0 in revenue, down 100.0% from the same quarter a year earlier. Immunome reported a net loss of $73.1 million, compared with a loss of $43.4 million a year earlier. Diluted earnings per share came in at -$0.65.
Summary generated from market data by MetaCap's automated system. Methodology
Immunome income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 4.01M | 2.93M | 2.74M | 2.91M | 2.36M | 1.03M | 3.83M | 3.56M |
| Revenue growth (YoY) | -100.00% | -100.00% | -100.00% | -100.00% | +69.84% | +184.35% | -28.44% | -18.37% | -44.55% | -56.47% | — | — |
| Operating Expenses | 78.14M | 59.33M | 72.86M | 60.14M | 50.49M | 47.56M | 85.71M | 53.43M | 42.37M | 133.33M | 98.48M | 8.20M |
| Research & Development | 59.88M | 46.38M | 50.77M | 49.19M | 40.45M | 36.87M | 47.89M | 37.20M | 29.08M | 15.37M | 9.64M | 3.82M |
| Operating Income | -78.14M | -59.33M | -72.86M | -60.14M | -46.48M | -44.64M | -82.97M | -50.52M | -40.01M | -132.30M | -94.65M | -4.63M |
| Net Income | -73.13M | -53.84M | -69.90M | -57.46M | -43.40M | -41.64M | -80.25M | -47.10M | -36.12M | -129.49M | -92.63M | -4.34M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.65 | -0.48 | -0.76 | -0.65 | -0.50 | -0.52 | -1.11 | -0.78 | -0.60 | -2.51 | -4.21 | -0.36 |
| EPS (Diluted) | -0.65 | -0.48 | -0.76 | -0.65 | -0.50 | -0.52 | -1.11 | -0.78 | -0.60 | -2.51 | -4.21 | -0.36 |
| Shares Outstanding (Basic) | 113.27M | 113.14M | — | 87.96M | 87.01M | 79.41M | — | 60.21M | 59.94M | 51.54M | — | 12.20M |
| Shares Outstanding (Diluted) | 113.27M | 113.14M | — | 87.96M | 87.01M | 79.41M | — | 60.21M | 59.94M | 51.54M | — | 12.20M |
| EBITDA | -77.18M | -58.73M | -72.23M | -59.55M | -45.84M | -44.02M | -82.52M | -50.11M | -39.46M | -132.14M | -94.50M | -4.52M |
| Operating Margin | — | — | — | — | -1157.61% | -1525.50% | -3030.31% | -1736.15% | -1692.43% | -12857.05% | -2473.94% | -129.96% |
| Net Margin | — | — | — | — | -1080.87% | -1423.10% | -2930.93% | -1618.56% | -1528.00% | -12584.26% | -2421.17% | -121.88% |
This table shows 12 quarterly periods of Immunome's income statement, from Q2 2026 back to Q3 2023, across 12 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow IMNM's reporting calendar. What is a income statement?